TP53 Signature Can Predict Pathological Response From Neoadjuvant Chemotherapy and Is a Prognostic Factor in Patients With Residual Disease.
Breast Cancer (Auckl). 2023 May 2;17:11782234231167655. doi: 10.1177/11782234231167655. eCollection 2023.
Breast Cancer (Auckl). 2023.
PMID: 37181950
Free PMC article.